BACKGROUND: Transmitted drug resistance (TDR) is critical to managing HIV-1-infected individuals and being a public health concern. We report on TDR prevalence and include analyses of phylogenetic clustering of HIV-1 in a predominantly men who have sex with men cohort diagnosed during acute/recent HIV-1 infection in New York City. METHODS: Genotypic resistance testing was conducted on plasma samples of 600 individuals with acute/recent HIV-1 infection (1995-2010). Sequences were used for resistance and phylogenetic analyses. Demographic and clinical data were abstracted from medical records. TDR was defined according to International AIDS Society-USA and Stanford HIV database guidelines. Phylogenetic and other analyses were conducted using PAUP*4.0 and SAS, respectively. RESULTS: The mean duration since HIV-1 infection was 66.5 days. TDR prevalence was 14.3% and stably ranged between 10.8% and 21.6% (P(trend) = 0.42). Nucleoside reverse transcriptase inhibitors resistance declined from 15.5% to 2.7% over the study period (P(trend) = 0.005). M41L (3.7%), T215Y (4.0%), and K103N/S (4.7%) were the most common mutations. K103N/S prevalence increased from 1.9% to 8.0% between 1995 and 2010 (P(trend) = 0.04). Using a rigorous definition of clustering, 19.3% (112 of 581) of subtype B viral sequences cosegregated into transmission clusters and clusters increased over time. There were fewer and smaller transmission clusters than had been reported in a similar cohort in Montreal but similar to reports from elsewhere. CONCLUSIONS: TDR is stable in this cohort and remains a significant concern to both individual patient management and the public health.
BACKGROUND: Transmitted drug resistance (TDR) is critical to managing HIV-1-infected individuals and being a public health concern. We report on TDR prevalence and include analyses of phylogenetic clustering of HIV-1 in a predominantly men who have sex with men cohort diagnosed during acute/recent HIV-1 infection in New York City. METHODS: Genotypic resistance testing was conducted on plasma samples of 600 individuals with acute/recent HIV-1 infection (1995-2010). Sequences were used for resistance and phylogenetic analyses. Demographic and clinical data were abstracted from medical records. TDR was defined according to International AIDS Society-USA and Stanford HIV database guidelines. Phylogenetic and other analyses were conducted using PAUP*4.0 and SAS, respectively. RESULTS: The mean duration since HIV-1 infection was 66.5 days. TDR prevalence was 14.3% and stably ranged between 10.8% and 21.6% (P(trend) = 0.42). Nucleoside reverse transcriptase inhibitors resistance declined from 15.5% to 2.7% over the study period (P(trend) = 0.005). M41L (3.7%), T215Y (4.0%), and K103N/S (4.7%) were the most common mutations. K103N/S prevalence increased from 1.9% to 8.0% between 1995 and 2010 (P(trend) = 0.04). Using a rigorous definition of clustering, 19.3% (112 of 581) of subtype B viral sequences cosegregated into transmission clusters and clusters increased over time. There were fewer and smaller transmission clusters than had been reported in a similar cohort in Montreal but similar to reports from elsewhere. CONCLUSIONS: TDR is stable in this cohort and remains a significant concern to both individual patient management and the public health.
Authors: Oliver Laeyendecker; Ron Brookmeyer; Amy E Oliver; Caroline E Mullis; Kevin P Eaton; Amy C Mueller; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Charles R Rinaldo; Thomas C Quinn; Susan H Eshleman Journal: AIDS Res Hum Retroviruses Date: 2011-12-01 Impact factor: 2.205
Authors: Linda Harrison; Hannah Castro; Patricia Cane; Deenan Pillay; Clare Booth; Andrew Phillips; Anna Maria Geretti; David Dunn Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: Manon Ragonnet-Cronin; Marianna Ofner-Agostini; Harriet Merks; Richard Pilon; Michael Rekart; Chris P Archibald; Paul A Sandstrom; James I Brooks Journal: J Acquir Immune Defic Syndr Date: 2010-09 Impact factor: 3.731
Authors: William H Wheeler; Rebecca A Ziebell; Helena Zabina; Danuta Pieniazek; Joseph Prejean; Ulana R Bodnar; Kristen C Mahle; Walid Heneine; Jeffrey A Johnson; H Irene Hall Journal: AIDS Date: 2010-05-15 Impact factor: 4.177
Authors: Vikram S Gill; Viviane D Lima; Wen Zhang; Brian Wynhoven; Benita Yip; Robert S Hogg; Julio S G Montaner; P Richard Harrigan Journal: Clin Infect Dis Date: 2010-01-01 Impact factor: 9.079
Authors: Shui Shan Lee; Dennise K P Tam; Yi Tan; Wai Lai Mak; Ka Hing Wong; Jonathan H K Chen; Wing Cheong Yam Journal: AIDS Date: 2009-08-24 Impact factor: 4.177
Authors: Jurgen Vercauteren; Annemarie M J Wensing; David A M C van de Vijver; Jan Albert; Claudia Balotta; Osamah Hamouda; Claudia Kücherer; Daniel Struck; Jean-Claude Schmit; Birgitta Asjö; Marie Bruckova; Ricardo J Camacho; Bonaventura Clotet; Suzie Coughlan; Zehava Grossman; Andrzej Horban; Klaus Korn; Leondios Kostrikis; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Elisabeth Puchhammer-Stöckl; Chiara Riva; Lidia Ruiz; Mika Salminen; Rob Schuurman; Anders Sonnerborg; Danica Stanekova; Maja Stanojevic; Anne-Mieke Vandamme; Charles A B Boucher Journal: J Infect Dis Date: 2009-11-15 Impact factor: 5.226
Authors: Vivek Jain; Teri Liegler; Eric Vittinghoff; Wendy Hartogensis; Peter Bacchetti; Lauren Poole; Lisa Loeb; Christopher D Pilcher; Robert M Grant; Steven G Deeks; Frederick M Hecht Journal: PLoS One Date: 2010-12-10 Impact factor: 3.240
Authors: Dana K Pasquale; Irene A Doherty; Lynne A Sampson; Stephane Hué; Peter A Leone; Joseph Sebastian; Sue L Ledford; Joseph J Eron; William C Miller; Ann M Dennis Journal: J Acquir Immune Defic Syndr Date: 2018-08-01 Impact factor: 3.731
Authors: J D Baxter; D Dunn; E White; S Sharma; A M Geretti; M J Kozal; M A Johnson; S Jacoby; J M Llibre; J Lundgren Journal: HIV Med Date: 2015-04 Impact factor: 3.180
Authors: Shan Hui; Fangfang Chen; Yi Li; Yan Cui; Jinhui Zhang; Ling Zhang; Yisi Yang; Yanlin Liu; Yashuang Zhao; Fan Lv Journal: Front Public Health Date: 2022-06-02
Authors: Martin Markowitz; Howard Grossman; Peter L Anderson; Robert Grant; Monica Gandhi; Howard Horng; Hiroshi Mohri Journal: J Acquir Immune Defic Syndr Date: 2017-12-01 Impact factor: 3.731
Authors: Kristina Rodriguez; Delivette Castor; Timothy L Mah; Stephanie H Cook; Lex M Auguiste; Perry N Halkitis; Marty Markowitz Journal: AIDS Care Date: 2013-01-11
Authors: Juan Ambrosioni; Omar Sued; David Nicolas; Marta Parera; María López-Diéguez; Anabel Romero; Fernando Agüero; María Ángeles Marcos; Christian Manzardo; Laura Zamora; Manuel Gómez-Carrillo; José María Gatell; Tomás Pumarola; José María Miró Journal: PLoS One Date: 2015-06-03 Impact factor: 3.240
Authors: Nicholas Bbosa; Deogratius Ssemwanga; Rebecca N Nsubuga; Noah Kiwanuka; Bernard S Bagaya; John M Kitayimbwa; Alfred Ssekagiri; Gonzalo Yebra; Pontiano Kaleebu; Andrew Leigh-Brown Journal: Viruses Date: 2021-05-24 Impact factor: 5.048